Sang D K, Ouma J H, John C C, Whalen C C, King C L, Mahmoud A A, Heinzel F P
Division of Vector Borne Diseases, Ministry of Health, Nairobi, Kenya.
J Infect Dis. 1999 Mar;179(3):743-6. doi: 10.1086/314635.
Kenyan subjects with visceral leishmaniasis were examined for evidence of increased production of soluble interleukin-4 receptor (sIL-4R). Soluble IL-4R regulates the bioactivity of IL-4, a cytokine important in mediating progressive forms of leishmaniasis. Persons with visceral leishmaniasis sustained 8- to 10-fold more circulating sIL-4R compared with Papua New Guinea residents with documented filariasis or uninfected Kenyan and North American subjects. Soluble IL-2R concentrations were elevated nonspecifically in both visceral leishmaniasis and filariasis patients. These findings are significant given that IL-4 induces sIL-4R in mice, and treatment with recombinant sIL-4R cures progressive murine leishmaniasis dependent on IL-4 bioactivity. Further studies are indicated to determine whether the immunologic detection of IL-4 produced in human visceral leishmaniasis is obscured because of sequestration by soluble receptor and whether the production of sIL-4R is relevant to the pathogenesis of visceral leishmaniasis.
对患有内脏利什曼病的肯尼亚受试者进行了检查,以寻找可溶性白细胞介素-4受体(sIL-4R)产生增加的证据。可溶性IL-4R调节IL-4的生物活性,IL-4是一种在介导利什曼病进展形式中起重要作用的细胞因子。与有丝虫病记录的巴布亚新几内亚居民或未感染的肯尼亚和北美受试者相比,内脏利什曼病患者循环中的sIL-4R含量高出8至10倍。可溶性IL-2R浓度在内脏利什曼病患者和丝虫病患者中均非特异性升高。鉴于IL-4在小鼠中诱导sIL-4R,并且用重组sIL-4R治疗可治愈依赖于IL-4生物活性的进行性小鼠利什曼病,这些发现具有重要意义。需要进一步研究以确定人类内脏利什曼病中产生的IL-4的免疫学检测是否因可溶性受体的隔离而受到影响,以及sIL-4R的产生是否与内脏利什曼病的发病机制相关。